Enhancement of ECT benefit by yohimbine.
Three patients with major depression who were pretreated with yohimbine 10 mg p.o. showed a dramatic response without major adverse effects following two electroconvulsive treatments (ECT). The hypothesis that the alpha 2-adrenergic antagonist yohimbine accelerates ECT-induced postsynaptic beta-adrenergic receptor down-regulation is discussed.
D000284:Administration, Oral; D000368:Aged; D003866:Depressive Disorder / Q000523:psychology / Q000628:therapy*; D004565:Electroconvulsive Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D015016:Yohimbine / Q000008:administration & dosage* / Q000494:pharmacology
D011943:Receptors, Adrenergic, beta; D015016:Yohimbine